An FDA advisory committee meets next week to examine how best to study the risks presented by drugs for attention deficit hyperactivity disorder while still allowing physicians to prescribe them. One of the drugs expected to be scrutinized is Shire's Adderall, which was associated with 20 deaths but is on the market in Canada and the U.S. A Shire representative says the company will have representatives at the meeting but they are not scheduled to speak.

Related Summaries